A Phase 1, Randomized, Open-Label, 2-Period, Crossover Design Study to Assess the Effects of Multiple Oral Doses of Lansoprazole, Dexlansoprazole, Omeprazole or Esomeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Subjects.
Latest Information Update: 09 Nov 2021
Price :
$35 *
At a glance
- Drugs Clopidogrel (Primary) ; Dexlansoprazole (Primary) ; Esomeprazole (Primary) ; Lansoprazole (Primary) ; Omeprazole (Primary)
- Indications Acute coronary syndromes; Dyspepsia; Gastritis; Gastro-oesophageal reflux; Myocardial ischaemia; NSAID-induced ulcer; Peptic ulcer; Peripheral arterial occlusive disorders; Stroke; Thrombosis
- Focus Pharmacodynamics; Pharmacogenomic; Pharmacokinetics
- 06 Sep 2011 Actual initiation date changed from Jan 2010 to Dec 2009 as reported by ClinicalTrials.gov.
- 05 Apr 2011 Results presented at the 60th Annual Scientific Session of the American College of Cardiology.
- 05 Apr 2011 Results presented at the 60th Annual Scientific Session of the American College of Cardiology.